Department of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
J Cancer Res Ther. 2022 Jul-Sep;18(4):921-926. doi: 10.4103/jcrt.JCRT_174_20.
Lymph node metastasis (LNM) is a point that often, treatment is not effective in colorectal cancer (CRC). Clinical and pathologic markers of prognosis help clinicians in selecting patients for adjuvant therapy after surgical resection in CRC. MiR-183-5p has been demonstrated to play as an oncogene in CRC, although its biological role still remains unclear. The aim of this study was to evaluate the expression of miR-183-5p in CRC and its potential relevance to clinicopathological characteristics as a prognostic biomarker.
In this case-control study, 33 CRC plasma samples at stage I-II-III, as well as plasma samples from 13 healthy controls, were collected. The relative expression levels of miR-183-5p in cancer and the normal samples were measured by quantitative real-time PCR. We analyzed their correlation with clinicopathological parameters and prognostic value.
Our results indicated that miR-183-5p was significantly overexpressed in CRC samples compared to healthy controls (P < 0.001) from a cutoff value of 3.9 with a sensitivity of 89% and a specificity of 91% and an AUC value of 0.74. Further analysis showed that a high plasma expression level of miR-183-5p was significantly associated with LNM and higher tumor/node/metastases stage (III) (P-value < 0.001).
In conclusion, the overexpression of miR-183-5p is highly related to advanced clinical stage, LNM and poor prognosis of CRC, indicating that miR-183-5p may serve as a predictive biomarker for the prognosis or the aggressiveness of CRC.
淋巴结转移（LNM）是结直肠癌（CRC）治疗效果不佳的一个关键点。临床和病理预后标志物有助于临床医生在 CRC 手术后选择辅助治疗的患者。miR-183-5p 已被证明在 CRC 中发挥癌基因作用，尽管其生物学作用仍不清楚。本研究旨在评估 miR-183-5p 在 CRC 中的表达及其作为预后生物标志物与临床病理特征的潜在相关性。
在这项病例对照研究中，收集了 33 例 I-II-III 期 CRC 血浆样本和 13 例健康对照者的血浆样本。通过实时定量 PCR 测量癌症和正常样本中 miR-183-5p 的相对表达水平。我们分析了它们与临床病理参数和预后价值的相关性。
我们的结果表明，与健康对照组相比，CRC 样本中 miR-183-5p 的表达显著升高（P<0.001），截断值为 3.9，灵敏度为 89%，特异性为 91%，AUC 值为 0.74。进一步分析表明，miR-183-5p 的高血浆表达水平与 LNM 和更高的肿瘤/淋巴结/转移分期（III 期）显著相关（P 值<0.001）。
miR-183-5p 的过表达与晚期临床分期、LNM 和 CRC 的不良预后高度相关，表明 miR-183-5p 可能作为 CRC 预后或侵袭性的预测生物标志物。
